These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. van Kuijk AW; Reinders-Blankert P; Smeets TJ; Dijkmans BA; Tak PP Ann Rheum Dis; 2006 Dec; 65(12):1551-7. PubMed ID: 16728461 [TBL] [Abstract][Full Text] [Related]
5. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663 [TBL] [Abstract][Full Text] [Related]
6. Current concepts in psoriatic arthritis: pathogenesis and management. de Vlam K; Gottlieb AB; Mease PJ Acta Derm Venereol; 2014 Nov; 94(6):627-34. PubMed ID: 24573106 [TBL] [Abstract][Full Text] [Related]
7. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Novelli L; Chimenti MS; Chiricozzi A; Perricone R Autoimmun Rev; 2014 Jan; 13(1):64-9. PubMed ID: 24021172 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Costa L; Caso F; Cantarini L; Del Puente A; Scarpa R; Atteno M Clin Rheumatol; 2014 Sep; 33(9):1355-7. PubMed ID: 24705820 [TBL] [Abstract][Full Text] [Related]
11. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Ogata A; Umegaki N; Katayama I; Kumanogoh A; Tanaka T Joint Bone Spine; 2012 Jan; 79(1):85-7. PubMed ID: 21962389 [TBL] [Abstract][Full Text] [Related]
12. Adalimumab in psoriatic arthritis. Salvarani C; Pipitone N; Catanoso M; Chiarolanza I; Boiardi L; Caruso A; Pazzola G; Macchioni P; Di Lernia V; Albertini G J Rheumatol Suppl; 2012 Jul; 89():77-81. PubMed ID: 22751600 [TBL] [Abstract][Full Text] [Related]
13. Interleukin (IL)-9/IL-9R axis drives γδ T cells activation in psoriatic arthritis patients. Guggino G; Ciccia F; Di Liberto D; Lo Pizzo M; Ruscitti P; Cipriani P; Ferrante A; Sireci G; Dieli F; Fourniè JJ; Giacomelli R; Triolo G Clin Exp Immunol; 2016 Dec; 186(3):277-283. PubMed ID: 27543964 [TBL] [Abstract][Full Text] [Related]
14. Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. Fiocco U; Martini V; Accordi B; Caso F; Costa L; Oliviero F; Scanu A; Felicetti M; Frallonardo P; Facco M; Boso D; Molena B; Zambello R; Ramonda R; Cozzi F; Scarpa R; Basso G; Semenzato G; Dayer JM; Doria A; Punzi L J Rheumatol Suppl; 2015 Nov; 93():48-52. PubMed ID: 26523057 [TBL] [Abstract][Full Text] [Related]
15. A short history of biological therapy for psoriatic arthritis. Mease P Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S104-8. PubMed ID: 26472182 [TBL] [Abstract][Full Text] [Related]
16. Treatment of psoriasis and psoriatic arthritis. Papoutsaki M; Costanzo A BioDrugs; 2013 Jan; 27 Suppl 1():3-12. PubMed ID: 23990277 [TBL] [Abstract][Full Text] [Related]
17. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. MclInnes IB Ernst Schering Res Found Workshop; 2006; (56):29-44. PubMed ID: 16329645 [TBL] [Abstract][Full Text] [Related]
18. Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis. Toussirot E Expert Opin Biol Ther; 2018 Jan; 18(1):101-107. PubMed ID: 29187009 [TBL] [Abstract][Full Text] [Related]